NAMS MENOPAUSE CERTIFICATION EXAM
(MSCP) 2026 – PRACTICE QUESTIONS WITH
VERIFIED ANSWERS & DETAILED
RATIONALES | MENOPAUSE SOCIETY
CERTIFIED PRACTITIONER TEST BANK |
COMPREHENSIVE WOMEN'S HEALTH EXAM
PREP GUIDE
NAMS MENOPAUSE CERTIFICATION EXAM (MSCP) 2026 – PRACTICE QUESTIONS
WITH VERIFIED ANSWERS & DETAILED EXPERT RATIONALE
• Comprehensive study resource – Contains practice questions covering all
domains of the NAMS Menopause Society Certified Practitioner exam, including
physiology, clinical management, pharmacology, and patient care strategies
• Exam-focused preparation – Use this material to master core menopause
concepts, test your knowledge across all competency areas, identify knowledge
gaps, and build confidence before your certification exam
1. Which of the following is the primary cause of vasomotor symptoms during
menopause?
A) Elevated estrogen levels triggering hypothalamic sensitivity
B) Decreased estrogen leading to narrowed thermoregulatory set point at the
hypothalamus
C) Increased progesterone causing central nervous system instability
D) Rising FSH levels directly stimulating sweat gland activity
E) Thyroid dysfunction resulting from ovarian failure
CORRECT ANSWER: B) Decreased estrogen leading to narrowed
thermoregulatory set point at the hypothalamus ✓
EXPERT RATIONALE: Vasomotor symptoms (hot flashes and night sweats) result
from estrogen deficiency causing a narrowed thermoregulatory zone in the
,hypothalamus. When core body temperature rises slightly, the hypothalamus
perceives it as excessive heat, triggering compensatory sweating and vasodilation.
This is the central mechanism recognized by the NAMS and supported by extensive
research. Elevated estrogen would not cause symptoms; FSH itself does not directly
trigger sweating; and thyroid dysfunction is not the primary cause.
2. A 52-year-old woman presents with 8 hot flashes daily and significant sleep
disruption. What is the first-line non-hormonal therapy recommended by
NAMS for moderate-to-severe vasomotor symptoms?
A) Vitamin E supplementation at high doses
B) Selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine
reuptake inhibitors (SNRIs)
C) Gabapentin as the preferred initial agent
D) Black cohosh herbal supplement
E) Acupuncture exclusively
CORRECT ANSWER: B) Selective serotonin reuptake inhibitors (SSRIs) or
serotonin-norepinephrine reuptake inhibitors (SNRIs) ✓
EXPERT RATIONALE: NAMS guidelines recommend SSRIs (paroxetine, fluoxetine,
sertraline, citalopram) and SNRIs (venlafaxine, desvenlafaxine) as first-line non-
hormonal treatments for moderate-to-severe vasomotor symptoms in women who
cannot or choose not to take hormone therapy. These agents reduce hot flash
frequency by 55-70%. Gabapentin is also effective but typically used as second-line.
Vitamin E has limited evidence, black cohosh shows modest effects, and
acupuncture lacks robust evidence.
3. Which hormone level best reflects the transition into menopause?
,A) Estradiol remains consistently high throughout menopause
B) FSH progressively increases as ovarian follicles deplete
C) Progesterone levels stabilize during perimenopause
D) LH decreases gradually over time
E) Inhibin A remains elevated until complete menopause
CORRECT ANSWER: B) FSH progressively increases as ovarian follicles deplete
✓
EXPERT RATIONALE: As the ovary approaches menopause, declining inhibin B and
estradiol lead to increased FSH secretion due to loss of negative feedback. FSH
levels greater than 30 IU/L in the follicular phase suggest menopause or late
perimenopause. FSH is the most reliable biochemical marker of menopausal
transition. Estradiol becomes erratically low, progesterone becomes unpredictable,
and inhibin levels decline significantly during perimenopause.
4. A woman in late perimenopause reports irregular menstrual cycles with
60+ day intervals. What is the expected endometrial thickness on
transvaginal ultrasound in the absence of abnormal bleeding?
A) Greater than 16 mm always requires endometrial sampling
B) Less than 5 mm generally excludes endometrial pathology
C) 4-8 mm is normal and does not require further evaluation in asymptomatic
women
D) Thickness greater than 10 mm is diagnostic of endometrial hyperplasia
E) Endometrial assessment is unnecessary during perimenopause
CORRECT ANSWER: C) 4-8 mm is normal and does not require further
evaluation in asymptomatic women ✓
, EXPERT RATIONALE: In postmenopausal women, endometrial thickness ≤4 mm is
normal; 5-8 mm is acceptable in the absence of symptoms. In perimenopausal
women with irregular bleeding, endometrial thickness measurement helps assess
risk. Thickness >8 mm with postmenopausal bleeding warrants further
investigation. However, in asymptomatic women, mild thickening during
perimenopause is expected due to erratic hormonal levels and does not
automatically require biopsy.
5. What is the most common type of endometrial cancer seen in
postmenopausal women with unopposed estrogen exposure?
A) Squamous cell carcinoma
B) Adenocarcinoma, specifically endometrioid type
C) Uterine sarcoma
D) Carcinosarcoma (malignant mixed Müllerian tumor)
E) Clear cell carcinoma
CORRECT ANSWER: B) Adenocarcinoma, specifically endometrioid type ✓
EXPERT RATIONALE: Endometrioid adenocarcinoma is the most frequent
endometrial cancer type (70-80% of cases), and unopposed estrogen exposure is a
major risk factor, particularly in obese postmenopausal women. It typically presents
as early-stage disease with abnormal bleeding. Other histologic types (sarcoma,
clear cell, carcinosarcoma) are less common and have worse prognoses.
Understanding this association is critical for counseling women on hormone
therapy risks, especially without progestin protection.
6. A 55-year-old woman is considering hormone therapy for moderate hot
flashes. She has no contraindications to HT. What is the maximum
(MSCP) 2026 – PRACTICE QUESTIONS WITH
VERIFIED ANSWERS & DETAILED
RATIONALES | MENOPAUSE SOCIETY
CERTIFIED PRACTITIONER TEST BANK |
COMPREHENSIVE WOMEN'S HEALTH EXAM
PREP GUIDE
NAMS MENOPAUSE CERTIFICATION EXAM (MSCP) 2026 – PRACTICE QUESTIONS
WITH VERIFIED ANSWERS & DETAILED EXPERT RATIONALE
• Comprehensive study resource – Contains practice questions covering all
domains of the NAMS Menopause Society Certified Practitioner exam, including
physiology, clinical management, pharmacology, and patient care strategies
• Exam-focused preparation – Use this material to master core menopause
concepts, test your knowledge across all competency areas, identify knowledge
gaps, and build confidence before your certification exam
1. Which of the following is the primary cause of vasomotor symptoms during
menopause?
A) Elevated estrogen levels triggering hypothalamic sensitivity
B) Decreased estrogen leading to narrowed thermoregulatory set point at the
hypothalamus
C) Increased progesterone causing central nervous system instability
D) Rising FSH levels directly stimulating sweat gland activity
E) Thyroid dysfunction resulting from ovarian failure
CORRECT ANSWER: B) Decreased estrogen leading to narrowed
thermoregulatory set point at the hypothalamus ✓
EXPERT RATIONALE: Vasomotor symptoms (hot flashes and night sweats) result
from estrogen deficiency causing a narrowed thermoregulatory zone in the
,hypothalamus. When core body temperature rises slightly, the hypothalamus
perceives it as excessive heat, triggering compensatory sweating and vasodilation.
This is the central mechanism recognized by the NAMS and supported by extensive
research. Elevated estrogen would not cause symptoms; FSH itself does not directly
trigger sweating; and thyroid dysfunction is not the primary cause.
2. A 52-year-old woman presents with 8 hot flashes daily and significant sleep
disruption. What is the first-line non-hormonal therapy recommended by
NAMS for moderate-to-severe vasomotor symptoms?
A) Vitamin E supplementation at high doses
B) Selective serotonin reuptake inhibitors (SSRIs) or serotonin-norepinephrine
reuptake inhibitors (SNRIs)
C) Gabapentin as the preferred initial agent
D) Black cohosh herbal supplement
E) Acupuncture exclusively
CORRECT ANSWER: B) Selective serotonin reuptake inhibitors (SSRIs) or
serotonin-norepinephrine reuptake inhibitors (SNRIs) ✓
EXPERT RATIONALE: NAMS guidelines recommend SSRIs (paroxetine, fluoxetine,
sertraline, citalopram) and SNRIs (venlafaxine, desvenlafaxine) as first-line non-
hormonal treatments for moderate-to-severe vasomotor symptoms in women who
cannot or choose not to take hormone therapy. These agents reduce hot flash
frequency by 55-70%. Gabapentin is also effective but typically used as second-line.
Vitamin E has limited evidence, black cohosh shows modest effects, and
acupuncture lacks robust evidence.
3. Which hormone level best reflects the transition into menopause?
,A) Estradiol remains consistently high throughout menopause
B) FSH progressively increases as ovarian follicles deplete
C) Progesterone levels stabilize during perimenopause
D) LH decreases gradually over time
E) Inhibin A remains elevated until complete menopause
CORRECT ANSWER: B) FSH progressively increases as ovarian follicles deplete
✓
EXPERT RATIONALE: As the ovary approaches menopause, declining inhibin B and
estradiol lead to increased FSH secretion due to loss of negative feedback. FSH
levels greater than 30 IU/L in the follicular phase suggest menopause or late
perimenopause. FSH is the most reliable biochemical marker of menopausal
transition. Estradiol becomes erratically low, progesterone becomes unpredictable,
and inhibin levels decline significantly during perimenopause.
4. A woman in late perimenopause reports irregular menstrual cycles with
60+ day intervals. What is the expected endometrial thickness on
transvaginal ultrasound in the absence of abnormal bleeding?
A) Greater than 16 mm always requires endometrial sampling
B) Less than 5 mm generally excludes endometrial pathology
C) 4-8 mm is normal and does not require further evaluation in asymptomatic
women
D) Thickness greater than 10 mm is diagnostic of endometrial hyperplasia
E) Endometrial assessment is unnecessary during perimenopause
CORRECT ANSWER: C) 4-8 mm is normal and does not require further
evaluation in asymptomatic women ✓
, EXPERT RATIONALE: In postmenopausal women, endometrial thickness ≤4 mm is
normal; 5-8 mm is acceptable in the absence of symptoms. In perimenopausal
women with irregular bleeding, endometrial thickness measurement helps assess
risk. Thickness >8 mm with postmenopausal bleeding warrants further
investigation. However, in asymptomatic women, mild thickening during
perimenopause is expected due to erratic hormonal levels and does not
automatically require biopsy.
5. What is the most common type of endometrial cancer seen in
postmenopausal women with unopposed estrogen exposure?
A) Squamous cell carcinoma
B) Adenocarcinoma, specifically endometrioid type
C) Uterine sarcoma
D) Carcinosarcoma (malignant mixed Müllerian tumor)
E) Clear cell carcinoma
CORRECT ANSWER: B) Adenocarcinoma, specifically endometrioid type ✓
EXPERT RATIONALE: Endometrioid adenocarcinoma is the most frequent
endometrial cancer type (70-80% of cases), and unopposed estrogen exposure is a
major risk factor, particularly in obese postmenopausal women. It typically presents
as early-stage disease with abnormal bleeding. Other histologic types (sarcoma,
clear cell, carcinosarcoma) are less common and have worse prognoses.
Understanding this association is critical for counseling women on hormone
therapy risks, especially without progestin protection.
6. A 55-year-old woman is considering hormone therapy for moderate hot
flashes. She has no contraindications to HT. What is the maximum
